J Pediatr Health Care:1型糖尿病青少年患者的压力源

2016-05-25 MedSci MedSci原创

1型糖尿病是最常见的儿科疾病之一,本文探讨了1型糖尿病青少年患者的常见压力和与糖尿病相关的压力源。研究纳入了205例对象,其中58%为女性,33%为少数民族,年龄在11-14岁之间。记录青少年心目中压力的前三名以及对开放性问题的答案。采用内容分析法探讨他们压力源的种类。研究结果显示82%的青少年认为最大的压力源是学校,紧接着是社会生活(49%)和糖尿病(48%)。研究人员明确了5类日常生活中的压力

1型糖尿病是最常见的儿科疾病之一,本文探讨了1型糖尿病青少年患者的常见压力和与糖尿病相关的压力源。

研究纳入了205例对象,其中58%为女性,33%为少数民族,年龄在11-14岁之间。记录青少年心目中压力的前三名以及对开放性问题的答案。采用内容分析法探讨他们压力源的种类。

研究结果显示82%的青少年认为最大的压力源是学校,紧接着是社会生活(49%)和糖尿病(48%)。研究人员明确了5类日常生活中的压力源(包括与他人相处、交友、平衡竞争需求、与家人相处和做好一件事的压力),以及3类糖尿病相关的压力源(包括患有糖尿病、情绪的处理和糖尿病管理)。

尽管患有1型糖尿病的青少年们经历着糖尿病相关的压力,但是他们更多的压力源于青少年的成长发育。因此1型糖尿病的青少年患者们可能需要成长发育方面或者糖尿病相关的心理支持。

原始出处:

Chao AM,Minges KE,Park C,et al.General Life and Diabetes-related Stressors in Early Adolescents With Type 1 Diabetes.J Pediatr Health Care. 2016;30(2):133-142.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1637353, encodeId=2aa9163e353e1, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jun 04 04:09:00 CST 2016, time=2016-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861057, encodeId=aaac186105e0e, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Jul 21 15:09:00 CST 2016, time=2016-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726107, encodeId=45091e2610705, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 10 05:09:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88148, encodeId=14b38814860, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:41:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621576, encodeId=77d616215e6eb, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri May 27 08:09:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1637353, encodeId=2aa9163e353e1, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jun 04 04:09:00 CST 2016, time=2016-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861057, encodeId=aaac186105e0e, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Jul 21 15:09:00 CST 2016, time=2016-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726107, encodeId=45091e2610705, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 10 05:09:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88148, encodeId=14b38814860, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:41:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621576, encodeId=77d616215e6eb, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri May 27 08:09:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-07-21 shizhenshan
  3. [GetPortalCommentsPageByObjectIdResponse(id=1637353, encodeId=2aa9163e353e1, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jun 04 04:09:00 CST 2016, time=2016-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861057, encodeId=aaac186105e0e, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Jul 21 15:09:00 CST 2016, time=2016-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726107, encodeId=45091e2610705, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 10 05:09:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88148, encodeId=14b38814860, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:41:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621576, encodeId=77d616215e6eb, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri May 27 08:09:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2017-03-10 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1637353, encodeId=2aa9163e353e1, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jun 04 04:09:00 CST 2016, time=2016-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861057, encodeId=aaac186105e0e, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Jul 21 15:09:00 CST 2016, time=2016-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726107, encodeId=45091e2610705, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 10 05:09:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88148, encodeId=14b38814860, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:41:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621576, encodeId=77d616215e6eb, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri May 27 08:09:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-06-02 沉心多思

    好文章,得多学习了!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1637353, encodeId=2aa9163e353e1, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jun 04 04:09:00 CST 2016, time=2016-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861057, encodeId=aaac186105e0e, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Jul 21 15:09:00 CST 2016, time=2016-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726107, encodeId=45091e2610705, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 10 05:09:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88148, encodeId=14b38814860, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:41:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621576, encodeId=77d616215e6eb, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri May 27 08:09:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]

相关资讯

JAMA:出生后6个月内发生复发性病毒性呼吸道感染可增加1型糖尿病的发生风险

JAMA:出生后6个月内发生复发性病毒性呼吸道感染可增加1型糖尿病的发生风险发表在JAMA上的一项研究表明,新生儿出生后前6个月内发生复发性病毒性呼吸道感染与日后1型糖尿病的发生有关。该研究发现表明生命的最初半年对于机体的免疫系统和自身免疫的发展来说是至关重要的。研究人员检查了2005-2007年出生在巴伐利亚的295420名婴儿的医疗记录。其中,720名研究对象在中位随访8.5年期间诊断为1型糖

Diabetes Care:1型糖尿病患者进行强化治疗可长期降低心血管疾病风险

1型糖尿病患者的早期强化糖尿病治疗旨在实现接近正常的血糖,来降低血管并发症的早期发展。研究人员旨在糖尿病控制和并发症试验(DCCT)超过30年的随访过程中,评估强化治疗与常规治疗相比,是否影响心脑血管疾病的发病率。该DCCT随机分配1441名1型糖尿病患者接受强化与常规治疗,平均6.5年,随后研究人员对93%的患者在糖尿病干预和并发症的流行病学观察研究(EDIC)中进行监测。心血管疾病(非致死性心

JCI:是真的吗?细菌可引发1型糖尿病!

近日,一项刊登于国际杂志The Journal of Clinical Investigation上的研究论文中,来自卡迪夫大学的研究人员通过研究发现,细菌或可通过诱发机体免疫系统破坏产胰岛素的细胞在1型糖尿病的发病过程中扮演重要角色;此前研究人员发现,杀伤性T细胞可以通过破坏胰腺β细胞来导致1型糖尿病的发生。

盘点:1型糖尿病突破性疗法进展一览

目前,全球糖尿病患者近乎4亿,该病的发病原因包括遗传和环境两大因素,然而前糖尿病患者数目更加庞大,研究人员推测,截至2035年全球将有5.92亿糖尿病患者。 糖尿病分为1型和2型糖尿病,1型糖尿病,原名胰岛素依赖型糖尿病,多发生在儿童和青少年,也可发生于各种年龄。起病比较急剧,体内胰岛素绝对不足,容易发生酮症酸中毒,必须用胰岛素治疗才能获得满意疗效,否则将危及生命。 目前我国已成为全球糖尿

Diabetes Care:人工胰腺治疗1型糖尿病儿童

意大利帕多瓦大学信息工程部门的Claudio Cobelli博士和同事对30名5-9岁1型糖尿病儿童进行了一项随机交叉研究,患者进行3天人工胰腺和3天家长管理式传感器增强胰岛素泵治疗。两组均使用稀释Novolog(速效门冬胰岛素,Novo Nordisk),两种治疗方式间存在24小时的洗脱期。夜间低血糖发生率从传感器增强胰岛素泵治疗时的2.2%,下降到人工胰腺治疗时的0%(P = .002)。传感

Diabetes:1型糖尿病患者心血管疾病的风险

有关2型糖尿病的心血管危险因素已经为人们所熟知,而1型糖尿病却并非如此。然而1型糖尿病与年龄匹配的非糖尿病患者相比具有更高的罹患心血管疾病的风险。研究人员对糖尿病控制和并发症试验(DCCT)中的1型糖尿病患者进行了长期随访(平均27年)和危险因素的评估。ox比例风险回归模型用于评估传统的及新发现的危险因素,包括HbA1c、动脉粥样硬化性心血管事件(MACE)(包括致死性或非致死性心肌梗死或中风)以